• About
• Links
• Contact
• Sitemap
• 

The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global CNS diseases therapeutics market. The report analyzes the markets for CNS disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The scope of this report includes:

Annualized market data for the CNS diseases therapeutics market from 2000 to 2008, forecast forward to 2015

Analysis of the leading therapeutic segments including Alzheimer’s disease, Parkinson’s disease, Schizophrenia and Bipolar Disorder, Epilepsy, Major depressive disorder (MDD), anxiety and panic disorder, Attention Deficit Hyperactivity Disorder (ADHD) and Insomnia.

Analysis of the CNS diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the CNS diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Lundbeck A/S, AstraZeneca, Merck & Co, Pfizer Inc, UCB S.A., Bristol-Myers Squibb and Eli Lilly

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global CNS diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1 Table of Contents 4

• 1.1 List of Tables 9
• 1.2 List of Figures 15

2 Global CNS Therapeutics Market : Introduction 20

• 2.1 Disease Overview 20
• 2.2 Report Guidance 20

3 Global CNS Therapeutics Market: Market Characterization 22

• 3.1 Market Overview 22
• 3.2 Market Forecasts 24
• 3.3 Branded Versus Generics 25
• 3.4 Market Share by Disease Sectors 26
• 3.5 Average Cost of Therapy 26
• 3.6 Volume 28
• 3.7 Usage Patterns 29
• 3.7.1 Diseased Population 29
• 3.7.2 Treatment Seeking Population 30
• 3.7.3 Diagnosis Population 31
• 3.7.4 Prescription Population 32
• 3.7.5 Therapeutic Usage Patterns 33
• 3.8 Geographical Distribution 34
• 3.9 Market Drivers and Restraints 36
• 3.9.1 Market Drivers 36
• 3.9.2 Market Restraints 37
• 3.10 Unmet Needs 39
• 3.10.1 Alzheimer’s Disease 40
• 3.10.2 Parkinson’s Disease 40
• 3.10.3 Schizophrenia and bipolar Disorder 40
• 3.10.4 Depression 40
• 3.10.5 Insomnia 40
• 3.11 Key Market Trends 41
• 3.11.1 Increase in Disease Incidence and Prevalence Rates 41
• 3.11.2 Product Pipeline 41
• 3.11.3 Advertising and Commercialization 42
• 3.11.4 Regulatory trends – Current Reimbursement Scenario 42

4 Global Alzheimer’s Disease Therapeutics Market 44

• 4.1 Market Overview 44
• 4.2 Market Forecasts 44
• 4.3 Average Cost of Therapy 45
• 4.4 Volume 46
• 4.5 Usage Patterns 48
• 4.5.1 Diseased Population 48
• 4.5.2 Treatment Seeking Population 49
• 4.5.3 Diagnosis Population 50
• 4.5.4 Prescription Population 51
• 4.5.5 Therapeutic Usage Patterns 52
• 4.6 Product Analysis 53
• 4.6.1 Aricept 53
• 4.6.2 Exelon and Exelon Patch 54
• 4.6.3 Ebixa (Namenda) 55
• 4.6.4 Razadyne and Reminyl 55
• 4.7 Drug Pipeline Analysis 55

5 Global Parkinson’s Disease Therapeutics Market 59

• 5.1 Market Overview 59
• 5.2 Market Forecasts 59
• 5.3 Average Cost of Therapy 61
• 5.4 Volume 62
• 5.5 Usage Patterns 63
• 5.5.1 Diseased Population 63
• 5.5.2 Treatment Seeking Population 64
• 5.5.3 Diagnosis Population 65
• 5.5.4 Prescription Population 66
• 5.5.5 Therapeutic Usage Patterns 67
• 5.6 Product Analysis 68
• 5.6.1 Azilect 68
• 5.6.2 Stalevo/Comtan 69
• 5.6.3 Madopar 69
• 5.6.4 Neupro 69
• 5.6.5 Requip/Requip XL 70
• 5.6.6 Sifrol/Mirapex 70
• 5.6.7 Sinemet 70
• 5.7 Drug Pipeline Analysis 70

6 Global Schizophrenia and Bipolar Disorder Therapeutics Market 73

• 6.1 Market Overview 73
• 6.2 Market Forecasts 73
• 6.3 Average Cost of Therapy 75
• 6.4 Volume 76
• 6.5 Usage Patterns 77
• 6.5.1 Diseased Population 77
• 6.5.2 Treatment Seeking Population 78
• 6.5.3 Diagnosis Population 79
• 6.5.4 Prescription Population 80
• 6.5.5 Therapeutic Usage Patterns 81
• 6.6 Product Analysis 82
• 6.6.1 Abilify 82
• 6.6.2 Clozaril 83
• 6.6.3 Geodon/Zeldox 83
• 6.6.4 Invega 84
• 6.6.5 Risperdal/Risperdal Consta 85
• 6.6.6 Serdolect 85
• 6.6.7 Seroquel 85
• 6.6.8 Zyprexa 86
• 6.7 Drug Pipeline Analysis 86

7 Global Epilepsy Therapeutics Market 89

• 7.1 Market Overview 89
• 7.2 Market Forecasts 89
• 7.3 Average Cost of Therapy 90
• 7.4 Volume 91
• 7.5 Usage Patterns 92
• 7.5.1 Diseased Population 92
• 7.5.2 Treatment Seeking Population 93
• 7.5.3 Diagnosis Population 94
• 7.5.4 Prescription Population 95
• 7.5.5 Therapeutic Usage Patterns 96
• 7.6 Product Analysis 98
• 7.6.1 Depakine 98
• 7.6.2 Keppra/Keppra XR and Vimpat 98
• 7.6.3 Lamictal 99
• 7.6.4 Lyrica 100
• 7.6.5 Neurontin 100
• 7.6.6 Tegretol 100
• 7.6.7 Trileptal 100
• 7.6.8 Topamax 101
• 7.6.9 Vimpat 101
• 7.7 Drug Pipeline Analysis 101

8 Global MDD, Anxiety and Panic Disorder Therapeutics Market 103

• 8.1 Market Overview 103
• 8.2 Market Forecasts 103
• 8.3 Average Cost of Therapy 105
• 8.4 Volume 106
• 8.5 Usage Patterns 107
• 8.5.1 Diseased Population 107
• 8.5.2 Treatment Seeking Population 108
• 8.5.3 Diagnosis Population 109
• 8.5.4 Prescription Population 110
• 8.5.5 Therapeutic Usage Patterns 111
• 8.6 Product Analysis 112
• 8.6.1 Celexa 112
• 8.6.2 Cipralex 113
• 8.6.3 Cymbalta 113
• 8.6.4 Effexor 114
• 8.6.5 Lexapro 114
• 8.6.6 Pristiq 114
• 8.6.7 Seroxat/Paxil 114
• 8.6.8 Wellbutrin/Wellbutrin XL 115
• 8.6.9 Xanax 115
• 8.6.10 Zoloft 115
• 8.7 Drug Pipeline Analysis 115

9 Global ADHD Therapeutics Market 118

• 9.1 Market Overview 118
• 9.2 Market Forecasts 118
• 9.3 Average Cost of Therapy 120
• 9.4 Volume 121
• 9.5 Usage Patterns 121
• 9.5.1 Diseased Population 121
• 9.5.2 Treatment Seeking Population 122
• 9.5.3 Diagnosis Population 123
• 9.5.4 Prescription Population 124
• 9.5.5 Therapeutic Usage Patterns 125
• 9.6 Product Analysis 127
• 9.6.1 Adderall/Adderall XR 127
• 9.6.2 Concerta 127
• 9.6.3 Daytrana 127
• 9.6.4 Focalin/Retalin 128
• 9.6.5 Strattera 129
• 9.6.6 Vyvanse 129
• 9.7 Drug Pipeline Analysis 129

10 Global Insomnia Therapeutics Market 131

• 10.1 Market Overview 131
• 10.2 Market Forecasts 131
• 10.3 Average Cost of Therapy 133
• 10.4 Volume 134
• 10.5 Usage Patterns 135
• 10.5.1 Diseased Population 135
• 10.5.2 Treatment Seeking Population 136
• 10.5.3 Diagnosis Population 137
• 10.5.4 Prescription Population 138
• 10.5.5 Therapeutic Usage Patterns 138
• 10.6 Product Analysis 140
• 10.6.1 Halcion 140
• 10.6.2 Lunesta 140
• 10.6.3 Rozerem 141
• 10.6.4 Ambien/Stilnox/Ambien CR 141
• 10.6.5 Sonata 142
• 10.7 Drug Pipeline Analysis 142

11 Global CNS Therapeutics Market: The US Market 146

• 11.1 Market Overview 146
• 11.2 Market Forecasts 146
• 11.3 Average Cost of Therapy 148
• 11.4 Volume 149
• 11.5 Usage Patterns 149
• 11.5.1 Diseased Population 149
• 11.5.2 Treatment Seeking Population 151
• 11.5.3 Diagnosis Population 152
• 11.5.4 Prescription Population 153
• 11.5.5 Therapeutic Usage Patterns 154

12 Global CNS Therapeutics Market: The European Market 156

• 12.1 Market Overview 156
• 12.2 Market Forecasts 156
• 12.3 Average Cost of Therapy 157
• 12.4 Volume 158
• 12.5 Usage Patterns 159
• 12.5.1 Diseased Population 159
• 12.5.2 Treatment Seeking Population 160
• 12.5.3 Diagnosis Population 161
• 12.5.4 Prescription Population 162
• 12.5.5 Therapeutic Usage Patterns 163

13 Global CNS Therapeutics Market: The Japanese Market 165

• 13.1 Market Overview 165
• 13.2 Market Forecasts 165
• 13.3 Average Cost of Therapy 166
• 13.4 Volume 168
• 13.5 Usage Patterns 168
• 13.5.1 Diseased Population 168
• 13.5.2 Treatment Seeking Population 170
• 13.5.3 Diagnosis Population 170
• 13.5.4 Prescription Population 171
• 13.5.5 Therapeutic Usage Patterns 172

14 Global CNS Therapeutics Market: Competitive Landscape 175

• 14.1 Overview 175
• 14.2 Market Share Analysis 176
• 14.3 Competitive Profiling 178
• 14.3.1 AstraZeneca 179
• 14.3.2 Boehringer Ingelheim 179
• 14.3.3 Bristol-Myers Squibb 179
• 14.3.4 Eli Lilly 179
• 14.3.5 GlaxoSmithKline (GSK) 179
• 14.3.6 Johnson & Johnson 180
• 14.3.7 H. Lundbeck A/S 180
• 14.3.8 Novartis 180
• 14.3.9 Pfizer 181
• 14.3.10 Sanofi Aventis 181
• 14.3.11 Shire Pharmaceuticals 181
• 14.3.12 UCB Pharma 181
• 14.3.13 Wyeth 181

15 Global CNS Therapeutics Market: Strategic Consolidations 183

• 15.1 Mergers and Acquisitions 183
• 15.1.1 Overview 183
• 15.2 Licensing Agreements 185
• 15.2.1 Preclinical 187
• 15.2.2 Phase I 188
• 15.2.3 Phase II 189
• 15.2.4 Phase III 190
• 15.2.5 Approved 191

16 Global CNS Therapeutics Market : Appendix 193

• 16.1 Market Definitions 193
• 16.2 Abbreviations 193
• 16.3 Research Methodology 193
• 16.4 Coverage 194
• 16.5 Secondary Research 194
• 16.6 Primary Research 195
• 16.7 Models 195
• 16.8 Forecasts 195
• 16.8.1 Epidemiology-based Forecasting 195
• 16.9 Expert Panel Validation 197
• 16.10 Contact Us 198
• 16.11 Disclaimer 198

1.1 List of Tables

• Table 1: CNS Therapeutics Market, Global, Revenues ($m), 2000-2008 24
• Table 2: CNS Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 24
• Table 3: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008 25
• Table 4: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015 26
• Table 5: CNS Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 27
• Table 6: CNS Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 27
• Table 7: CNS Therapeutics Market, Global, Historical Figures for Volume (000), 2000-2008 28
• Table 8: CNS Therapeutics Market, Global, Forecasts for Volume, 2008-2015 28
• Table 9: CNS Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 29
• Table 10: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 29
• Table 11: CNS Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 30
• Table 12: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 30
• Table 13: CNS Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 31
• Table 14: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 31
• Table 15: CNS Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 32
• Table 16: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 32
• Table 17: CNS Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 33
• Table 18: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 34
• Table 19: CNS Therapeutics Market, Global, Market Drivers, 2008 36
• Table 20: CNS Therapeutics Market, Global, Market Restraints, 2008 37
• Table 21: CNS Therapeutics Market, Global, Major Drug Patent Expirations, 2008-2015 38
• Table 22: CNS Therapeutics Market, Global, Reimbursement Policies of Various 43
• Table 23: Alzheimer’s Disease Therapeutics Market, Historical Revenue ($m), 2000-2008 45
• Table 24: Alzheimer’s Disease Therapeutics Market, Revenue Forecasts ($m), 2008-2015 45
• Table 25: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 46
• Table 26: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 46
• Table 27: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 47
• Table 28: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Volume, 2008-2015 47
• Table 29: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 48
• Table 30: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 49
• Table 31: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 49
• Table 32: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 50
• Table 33: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 50
• Table 34: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 51
• Table 35: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 51
• Table 36: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 52
• Table 37: Alzheimer’s Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 53
• Table 38: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 53
• Table 39: Alzheimer’s Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 53
• Table 40: Alzheimer’s Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008 56
• Table 41: Parkinson’s Disease Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 60
• Table 42: Parkinson’s Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 61
• Table 43: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 61
• Table 44: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 62
• Table 45: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 62
• Table 46: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Volume, 2008-2015 63
• Table 47: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 64
• Table 48: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 64
• Table 49: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 65
• Table 50: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 65
• Table 51: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 66
• Table 52: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 66
• Table 53: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 67
• Table 54: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 67
• Table 55: Parkinson’s Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 68
• Table 56: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 68
• Table 57: Parkinson’s Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 68
• Table 58: Parkinson’s Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008 71
• Table 59: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 74
• Table 60: Schizophrenia and Bipolar Disorder Therapeutics Market, Global,, Revenue Forecasts ($m), 2008-2015 75
• Table 61: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 76
• Table 62: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 76
• Table 63: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 77
• Table 64: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015 77
• Table 65: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 78
• Table 66: Schizophrenia and Bipolar Disorder Therapeutics Market, Forecasts for Diseased Population, 2008-2015 78
• Table 67: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 79
• Table 68: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 79
• Table 69: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 80
• Table 70: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 80
• Table 71: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 81
• Table 72: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 81
• Table 73: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 82
• Table 74: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 82
• Table 75: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 83
• Table 76: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 86
• Table 77: Epilepsy Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 90
• Table 78: Epilepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 90
• Table 79: Epilepsy Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 91
• Table 80: Epilepsy Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 91
• Table 81: Epilepsy Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 92
• Table 82: Epilepsy Therapeutics Market, Global, Forecasts for Volume, 2008-2015 92
• Table 83: Epilepsy Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 93
• Table 84: Epilepsy Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 93
• Table 85: Epilepsy Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 94
• Table 86: Epilepsy Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 94
• Table 87: Epilepsy Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 95
• Table 88: Epilepsy Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 95
• Table 89: Epilepsy Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 96
• Table 90: Epilepsy Therapeutics Market, Forecasts for Prescription Population, 2008-2015 96
• Table 91: Epilepsy Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patters, 2000-2008 97
• Table 92: Epilepsy Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 97
• Table 93: Epilepsy Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 98
• Table 94: Epilepsy Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 101
• Table 95: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 104
• Table 96: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 104
• Table 97: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 105
• Table 98: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 105
• Table 99: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 106
• Table 100: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015 106
• Table 101: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 107
• Table 102: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 108
• Table 103: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historic Figures for Treatment Seeking Population, 2000-2008 108
• Table 104: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 109
• Table 105: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 109
• Table 106: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 110
• Table 107: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 110
• Table 108: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 111
• Table 109: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 112
• Table 110: MDD, Anxiety Panic Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 112
• Table 111: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 112
• Table 112: Global MDD, Panic and Anxiety Disorder Therapeutics Market, Clinical Trials Drug Portfolio, 2008 115
• Table 113: Global ADHD Therapeutics Market, Historical Revenues ($m), 2000-2008 119
• Table 114: Global ADHD Therapeutics Market, Revenues Forecasts ($million), 2008-2015 119
• Table 115: ADHD Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008 120
• Table 116: ADHD Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 120
• Table 117: Global ADHD Therapeutics Market, Historical Figures for Volume, 2000-2008 121
• Table 118: Global ADHD Therapeutics Market, Forecasts for Volume, 2008-2015 121
• Table 119: Global ADHD Therapeutics Market, Historical Figures for Diseased Population, 2000-2008 122
• Table 120: Global ADHD Therapeutics Market, Forecasts for Diseased Population, 2008-2015 122
• Table 121: Global ADHD Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008 123
• Table 122: Global ADHD Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015 123
• Table 123: Global ADHD Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008 124
• Table 124: Global ADHD Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015 124
• Table 125: Global ADHD Therapeutics Market, Historical Figures for Prescription Population, 2000-2008 125
• Table 126: Global ADHD Therapeutics Market, Forecasts for Prescription Population, 2008-2015 125
• Table 127: Global ADHD Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008 126
• Table 128: Global ADHD Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2008-2015 126
• Table 129: Global ADHD Therapeutics Market, Major Manufacturers and Drugs, 2008 127
• Table 130: Global Insomnia Therapeutics Market, Historical Revenues ($m), 2000-2008 132
• Table 131: Global Insomnia Therapeutics Market, Revenue Forecasts ($m), 2008-2015 132
• Table 132:Global Insomnia Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008 133
• Table 133: Global Insomnia Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 133
• Table 134: Insomnia Therapeutics Market, Historical Figures for Volume, 2000-2008 134
• Table 135: Insomnia Therapeutics Market, Forecasts for Volume, 2008-2015 134
• Table 136: Global Insomnia Therapeutics Market, Historical Figures for Diseased Population, 2000-2008 135
• Table 137: Global Insomnia Therapeutics Market, Forecasts for Diseased Population, 2008-2015 135
• Table 138: Global Insomnia Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008 136
• Table 139: Insomnia Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015 136
• Table 140: Global Insomnia Therapeutics Market,Historical Figures for Diagnosis Population, 2000-2008 137
• Table 141: Global Insomnia Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015 137
• Table 142: Global Insomnia Therapeutics Market, Historical Figures for Prescription Population, 2000-2008 138
• Table 143: Global Insomnia Therapeutics Market, Forecasts for Prescription Population, 2008-2015 138
• Table 144: Global Insomnia Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008 139
• Table 145: Global Insomnia Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2008-2015 139
• Table 146: Global Insomnia Therapeutics Market, Major Manufacturers and Drugs, 2008 140
• Table 147: Insomnia Therapeutics Market, Clinical Trials Pipeline, 2008 142
• Table 148: CNS Therapeutics Market, US, Historical Revenues ($m), 2000-2008 147
• Table 149: CNS Therapeutics Market, US, Revenue Forecasts ($m), 2008-2015 147
• Table 150: CNS Therapeutics Market, US, Historical Figures for the Average Cost of Therapy ($), 2000-2008 148
• Table 151: CNS Therapeutics Market, US, Forecasts for the Average Cost of Therapy ($), 2008-2015 148
• Table 152: CNS Therapeutics Market, US, Historical Figures for Volume, 2000-2008 149
• Table 153: CNS Therapeutics Market, US, Forecasts for Volume, 2008-2015 149
• Table 154: CNS Therapeutics Market, US, Historical Figures for Diseased Population, 2000-2008 150
• Table 155: CNS Therapeutics Market, US, Forecasts for Diseased Population, 2008-2015 151
• Table 156: CNS Therapeutics Market, US, Historical Figures for Treatment Seeking Population, 2000-2008 151
• Table 157: CNS Therapeutics Market, US, Forecasts for Treatment Seeking Population, 2008-2015 152
• Table 158: CNS Therapeutics Market, US, Historical Figures for Diagnosis Population, 2000-2008 153
• Table 159: CNS Therapeutics Market, US, Forecasts for Diagnosis Population, 2008-2015 153
• Table 160: CNS Therapeutics Market, US, Historical Figures for Prescription Population, 2000-2008 154
• Table 161:CNS Therapeutics Market, US, Forecasts for Prescription Population, 2008-2015 154
• Table 162:CNS Therapeutics Market, US, Historical Figures for Usage Patterns, 2000-2008 155
• Table163: CNS Therapeutics Market, US, Forecasts for Usage Patterns, 2008-2015 155
• Table 164: CNS Therapeutics Market, Europe, Historical Revenues ($m), 2000-2008 157
• Table 165: CNS Therapeutics Market, Europe, Revenue Forecasts ($m), 2008-2015 157
• Table 166: CNS Therapeutics Market, Europe, Historical Figures for Average Cost of Treatment, 2000-2008 158
• Table 167: CNS Therapeutics Market, Europe, Forecasts for Average Cost of Treatment, 2008-2015 158
• Table 168: CNS Therapeutics Market, Europe, Historical Figures for Volume, 2000-2008 159
• Table 169: CNS Therapeutics Market, Europe, Forecasts for Volume, 2008-2015 159
• Table 170: CNS Therapeutics Market, Europe, Historical Figures for Diseased Population, 2000-2008 160
• Table 171: CNS Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015 160
• Table 172: CNS Therapeutics Market, Europe, Historical Figures for Treatment Seeking Population, 2000-2008 161
• Table173: CNS Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015 161
• Table 174: CNS Therapeutics Market, Europe, Historical Figures for Diagnosis Population, 2000-2008 162
• Table 175: CNS Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015 162
• Table 176: CNS Therapeutics Market, Europe, Historical Figures for Prescription Population, 2000-2008 163
• Table 177: CNS Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015 163
• Table 178: CNS Therapeutics Market, Europe, Historical Figures for Therapeutic Usage Patterns, 2000-2008 164
• Table 179: CNS Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2008-2015 164
• Table 180: CNS Therapeutics Market, Japan, Historical Revenues ($m), 2000-2008 166
• Table 181:CNS Therapeutics Market, Japan, Revenue Forecasts ($m), 2008-2015 166
• Table 182: CNS Therapeutics Market, Japan, Historical Figures for Average Cost of Therapy ($), 2000-2008 167
• Table 183: CNS Therapeutics Market, Japan, Forecasts for Average Cost of Therapy ($), 2008-2015 167
• Table 184: CNS Therapeutics Market, Japan, Historical Figures for Volume, 2000-2008 168
• Table 185: CNS Therapeutics Market, Japan, Forecasts for Volume, 2008-2015 168
• Table 186: CNS Therapeutics Market, Japan, Historical Figures for Diseased Population, 2000-2008 169
• Table 187: CNS Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015 169
• Table 188: CNS Therapeutics Market, Japan, Historical Figures for Treatment Seeking Population, 2000-2008 170
• Table 189: CNS Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015 170
• Table 190: CNS Therapeutics Market, Japan, Historical Figures for Diagnosis Population, 2000-2008 171
• Table 191: CNS Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015 171
• Table 192: CNS Therapeutics Market, Japan, Historical Figures for Prescription Population, 2000-2008 172
• Table 193: CNS Therapeutics Market, Japan, Forecasts for Prescription Population, 2008-2015 172
• Table 194: CNS Therapeutics Market, Japan, Historical Figures for Therapeutic Usage Patterns, 2000-2008 173
• Table 195: CNS Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2008-2015 174
• Table 196: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008 187
• Table 197: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2008 188
• Table 198: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2008 189
• Table 199: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2008 190
• Table 200: CNS Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008 191

1.2 List of Figures

• Figure 1: CNS Therapeutics Market, Global, Market Overview, 2008 22
• Figure 2: CNS Therapeutics Market, Global, Key Geographical Trends, 2008 23
• Figure 3: CNS Therapeutics Market, Global, Revenue Forecasts ($bn), 2000-2015 24
• Figure 4: CNS Therapeutics Market, Global, Revenue Split ($bn), 2000-2015 25
• Figure 5: CNS Therapeutics Market, Global, Market Share of Major Disease Sectors, 2008 26
• Figure 6: Global CNS Therapeutics Market, Average Cost of Therapy ($), 2000-2015 27
• Figure 7: CNS Therapeutics Market, Global, Forecasts for Volume, 2000-2015 28
• Figure 8: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 29
• Figure 9: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 30
• Figure 10: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 31
• Figure 11: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 32
• Figure 12: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 33
• Figure 13: CNS Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015 34
• Figure 14: CNS Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008 35
• Figure 15: CNS Therapeutics Market, Global, Market Indicators, 2008 36
• Figure 16: CNS Therapeutics Market, Global, Analysis of Unmet Needs for Major Disease Sectors, 2008 39
• Figure 17: CNS Therapeutics Market, Global, Key Market Events, 2008-2015 41
• Figure 18: Alzheimer’s Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 44
• Figure 19: Alzheimer’s Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 46
• Figure 20: Alzheimer’s Disease Therapeutics Market, Global, Global,Forecasts for Volume, 2000-2015 47
• Figure 21: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 48
• Figure 22: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 49
• Figure 23: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 50
• Figure 24: Alzheimer’s Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 51
• Figure 25: Alzheimer’s Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 52
• Figure 26: Alzheimer’s Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008 54
• Figure 27: Alzheimer’s Disease Therapeutics Market, Global, Historical Revenues of Major Drugs ($m), 2006-2008 55
• Figure 28: Alzheimer’s Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Clinical Development, 2008 57
• Figure 29: Alzheimer’s Disease Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 57
• Figure 30: Alzheimer’s Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 58
• Figure 31: Parkinson’s Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 60
• Figure 32: Parkinson’s Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 61
• Figure 33: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Volume, 2000-2015 62
• Figure 34: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 63
• Figure 35: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 64
• Figure 36: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 65
• Figure 37: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 66
• Figure 38: Parkinson’s Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 67
• Figure 39: Parkinson’s Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008 69
• Figure 40: Parkinson’s Disease Therapeutics Market, Global, Historic Revenues of Major Drugs ($m), 2006-2008 70
• Figure 41: Parkinson’s Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008 71
• Figure 42: Parkinson’s Disease Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 72
• Figure 43: Parkinson’s Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 72
• Figure 44: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 74
• Figure 45: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 75
• Figure 46: Schizophrenia and Bipolar Disorder Therapeutics Markets, Global, Forecasts for Volume, 2000-2015 76
• Figure 47: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 77
• Figure 48: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 78
• Figure 49: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 79
• Figure 50: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 80
• Figure 51: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 81
• Figure 52: Schizophrenia and Bipolar Disorder Therapeutics Market, Market Share of Major Therapeutic Drugs, 2008 84
• Figure 53: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historic Revenues of Major Drugs, 2006-2008 85
• Figure 54: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008 86
• Figure 55: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 87
• Figure 56: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 88
• Figure 57: Epilepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 90
• Figure 58: Epilepsy Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015 91
• Figure 59: Epilepsy Therapeutics Market, Global, Forecasts for Volume, 2000-2015 92
• Figure 60: Epilepsy Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 93
• Figure 61: Epilepsy Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 94
• Figure 62: Epilepsy Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 95
• Figure 63: Epilepsy Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 96
• Figure 64: Epilepsy Therapeutics Market, Global, Forecasts for Therapeutics Usage Patterns, 2000-2015 97
• Figure 65: Epilepsy Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008 99
• Figure 66: Epilepsy Therapeutics Market, Global, Historic Revenues of Major Drugs, 2006-2008 100
• Figure 67: Epilepsy Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008 102
• Figure 68: Epilepsy Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 102
• Figure 69: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 104
• Figure 70: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 105
• Figure 71: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Volume, 2000-2015 106
• Figure 72: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 107
• Figure 73: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 108
• Figure 74: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 109
• Figure 75: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 110
• Figure 76: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Therapeutics Usage Patterns, 2000-2015 111
• Figure 77: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008 113
• Figure 78: Global MDD, Anxiety and Panic Disorder, Historic Revenues of Major Drugs, 2006-2008 114
• Figure 79: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008 116
• Figure 80: MDD, Anxiety and Panic Disorder Therapeutics Market, Major Manufacturers and their Pipeline Portfolios, 2008 117
• Figure 81: Global ADHD Therapeutics Market, Revenue Forecasts ($m), 2000-2015 119
• Figure 82: Global ADHD Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015 120
• Figure 83: Global ADHD Therapeutics Market, Forecasts for Volume, 2000-2015 121
• Figure 84: Global ADHD Therapeutics Market, Forecasts for Diseased Population, 2000-2015 122
• Figure 85: Global ADHD Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015 123
• Figure 86: Global ADHD Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015 124
• Figure 87: Global ADHD Therapeutics Market, Forecasts for Prescription Population, 2000-2015 125
• Figure 88: ADHD Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 126
• Figure 89: Global ADHD Therapeutics Market, Market Share of Major Therapeutic Drugs, 2008 128
• Figure 90: Global ADHD Therapeutics Market, Historic Revenues of Major Drugs ($m), 2006-2008 129
• Figure 91: Global ADHD Therapeutics Market, Share Assessment of Molecules Under Stages of Development, 2008 130
• Figure 92: Global ADHD Therapeutics Market, Major Manufacturers and their Pipeline Portfolio, 2008 130
• Figure 93: Global Insomnia Therapeutics Market, Revenue Forecasts ($m), 2000-2015 132
• Figure 94: Global Insomnia Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015 133
• Figure 95: Global Insomnia Therapeutics Market, Forecasts for Volume, 2000-2015 134
• Figure 96: Global Insomnia Therapeutics Market, Forecasts for Diseased Population, 2000-2015 135
• Figure 97: Global Insomnia Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015 136
• Figure 98: Global Insomnia Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015 137
• Figure 99: Global Insomnia Therapeutics Market, Forecasts for Prescription Population, 2000-2015 138
• Figure 100: Global Insomnia Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2000-2015 139
• Figure 101: Global Insomnia Therapeutics Market, Market Share of Major Therapeutic Drugs, 2008 141
• Figure 102: Global Insomnia Therapeutics Market, Historic Revenues of Major Drugs, 2006-2008 142
• Figure 103: Global Insomnia Therapeutics Market, Share Assessment of Molecules Under Stages of Development, 2008 143
• Figure 104: Global Insomnia Therapeutics Market, Clinical Trials Drug Portfolio , 2008 144
• Figure 105: Global Insomnia Therapeutics Market, Major Manufacturers and their Pipeline Portfolio, 2008 145
• Figure 106: CNS Therapeutics Market, US, Revenue Forecasts ($bn), 2000-2015 147
• Figure 107: CNS Therapeutics Market, US, Average Cost of Therapy ($), 2000-2015 148
• Figure 108: CNS Therapeutics Market, US, Forecasts for Volume (million), 2000-2015 149
• Figure 109: CNS Therapeutics Market, US, Forecasts for Diseased Population, 2000-2015 150
• Figure 110: CNS Therapeutics Market, US, Forecasts for Treatment Seeking Population, 2000-2015 151
• Figure 111: CNS Therapeutics Market, US, Forecasts for Diagnosis Population, 2000-2015 152
• Figure 112: CNS Therapeutics Market, US, Forecasts for Prescription Population, 2000-2015 153
• Figure 113: CNS Therapeutics Market, US, Forecasts for Therapeutic Usage Patterns, 2000-2015 154
• Figure 114: CNS Therapeutics Market, Europe, Revenue Forecasts ($bn), 2000-2015 157
• Figure 115: CNS Therapeutics Market, Europe, Forecasts for Average Cost of Treatment ($), 2000-2015 158
• Figure 116: CNS Therapeutics Market, Europe, Forecasts for Volume (m), 2000-2015 159
• Figure 117: CNS Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2015 160
• Figure 118: CNS Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2015 161
• Figure 119: CNS Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2015 162
• Figure 120: CNS Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2015 163
• Figure 121: CNS Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015 164
• Figure 122: CNS Therapeutics Market, Japan, Revenue Forecasts ($bn), 2000-2015 166
• Figure 123: CNS Therapeutics Market, Japan, Forecasts for Average Cost of Therapy ($), 2000-2015 167
• Figure 124: CNS Therapeutics Market, Japan, Forecasts for Volume, 2000-2015 168
• Figure 125: CNS Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2015 169
• Figure 126: CNS Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2015 170
• Figure 127: CNS Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2015 171
• Figure 128: CNS Therapeutics Market, Japan, Forecasts for Prescription Population, 2000-2015 172
• Figure 129: CNS Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2015 173
• Figure 130: CNS Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues ($m), 2006-08 175
• Figure 131: CNS Therapeutics Market, Global, Competitive Analysis of Top 6 Manufacturers, 2008-2015 176
• Figure 132: CNS Therapeutics Market, Global, Market Share of Top Manufacturers, 2008 177
• Figure 133: CNS Therapeutics Market, Global, Benchmarking Analysis for Top Four Manufacturers, 2008 178
• Figure 134: CNS Therapeutics Market, Global, Benchmarking Analysis for Top Four Manufacturers (Contd..), 2008 178
• Figure 135: CNS Therapeutics Market, Global, Comparative Analysis of Major Manufacturers with Respect to Market Presence, 2008 182
• Figure 136: CNS Therapeutics Market, Global, M&A Deals by Geography and Phase, 2008 183
• Figure 137: CNS Therapeutics Market, Global, M&A Deals by Value and Type, 2008 183
• Figure 138: CNS Therapeutics Market, Global, Top 3 M&A Deals, 2008 184
• Figure 139: CNS Therapeutics Market, Global, Licensing Agreement Share by Geography and Value, 2008 186
• Figure 140: CNS Therapeutics Market, Global, Licensing Agreement Share by Phases of Development and Disease Sector, 2008 186
• Figure 141: Research Methodology, November 2009 194
• Figure 142: Research Market Forecasting Model 197

Other users found this report page using the following search terms: Alzheimer disease Parkinson disease Schizophrenia and Bipolar Disorder Epilepsy Major depressive disorder MDD anxiety panic disorder Attention Deficit Hyperactivity Disorder ADHD Insomnia market cns desease global globalcentralnervoussystemforecastbydiseaseclass 20082015 trial clinical schizophrenia forecast population

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.